Mizolastine
![]() | |
Systematic (IUPAC) name | |
---|---|
2-[{1-[1-(4-fluorobenzyl)-1H-benzimidazol-2-yl]piperidin-4-yl}(methyl)amino]pyrimidin-4(1H)-one | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
Legal status |
|
Identifiers | |
CAS Number |
108612-45-9 ![]() |
ATC code | R06AX25 (WHO) |
PubChem | CID 65906 |
ChemSpider |
59315 ![]() |
UNII |
244O1F90NA ![]() |
KEGG |
D01117 ![]() |
ChEMBL |
CHEMBL94454 ![]() |
Chemical data | |
Formula | C24H25FN6O |
Molar mass | 432.493 g/mol |
| |
| |
![]() ![]() |
Mizolastine (Mizollen) is a once daily, non-sedating antihistamine. It blocks H1 receptors and is commonly fast-acting. It does not prevent the actual release of histamine from mast cells, just prevents it binding to receptors. Side effects can include dry mouth and throat.[1]
References
- ↑ "MIZOLASTINE: British National Formulary". Retrieved 2010-02-01.
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.